New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 18, 2012
08:47 EDTTEVATeva removed from short-term buy list at Deutsche Bank
Teva was removed due to an automatic time demotion.
News For TEVA From The Last 14 Days
Check below for free stories on TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
July 16, 2014
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
July 15, 2014
11:13 EDTTEVAPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
July 14, 2014
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
July 9, 2014
07:15 EDTTEVATeva, others fined $583.4M by EU regulators, Reuters says
Subscribe for More Information
06:49 EDTTEVAGeneric drug prices have risen significantly, NY Times says
Subscribe for More Information
July 8, 2014
07:03 EDTTEVAEagle Pharmaceuticals receives orphan drug designation for bendamustine HCl
Eagle Pharmaceuticals (EGRX) announced that the FDA has granted orphan drug designation to bendamustine hydrochloride, a ready-to-dilute concentrate solution for injection that will be administered by infusion over 10 minutes after dilution in 50mL of sodium chloride or a saline / dextrose mixture, for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Pursuant to the orphan drug designation, Eagle is eligible to receive tax incentives and Prescription Drug User Fee Act fee savings, and believes it may receive seven years of marketing exclusivity. The currently marketed bendamustine HCI product, Treanda, which is manufactured by Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries (TEVA), is a lyophilized powder requiring reconstitution and dilution in 500mL of saline or a sodium chloride / dextrose mixture before administration over 30 minutes for CLL and 60 minutes for NHL.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use